proper
intervent
extraglandular
manifest
although
awar
system
natur
consider
morbid
direct
treatment
toward
diseas
modif
treatment
sicca
symptom
immunomodulatori
drug
unsuccess
contrast
use
tear
saliva
substitut
may
provid
transient
relief
sicca
symptom
often
fail
prevent
ocular
dental
complic
henc
use
secretagogu
stimul
secret
exocrin
gland
repres
novel
approach
allevi
sicca
symptom
patient
ss
pilocarpin
natur
plant
alkaloid
deriv
south
american
shrub
pilocarpu
jaborandi
cholinerg
parasympathomimet
agonist
stimul
receptor
v
variou
exocrin
gland
lead
increas
secretori
function
inde
pilocarpin
hydrochlorid
mgi
pharma
inc
bloomington
mn
usa
approv
treatment
radiationinduc
dri
mouth
ss
patient
primari
secondari
ss
treatment
w
pilocarpin
may
allevi
sicca
symptom
increas
saliva
flow
control
studi
also
shown
pilocarpin
safe
well
toler
seriou
advers
effect
drug
interact
genet
predisposit
ethnic
affect
clinic
manifest
immunolog
featur
ss
differ
treatment
respons
pilocarpin
requir
investig
differ
popul
doubleblind
random
placebocontrol
trial
investig
clinic
efficaci
safeti
oral
pilocarpin
mg
four
time
daili
improv
oral
symptom
patient
ss
taiwan
patient
older
year
diagnosi
primari
secondari
ss
accord
american
colleg
rheumatolog
criteria
enrol
rheumatolog
outpati
clinic
nation
taiwan
univers
hospit
ntuh
april
novemb
r
diagnosi
primari
ss
patient
without
rheumat
disord
requir
presenc
four
follow
six
criteria
ocular
symptom
oral
symptom
ocular
sign
object
salic
vari
gland
involv
abnorm
histopatholog
featur
salivari
gland
presenc
antinuclear
antibodi
rheumatoid
factor
autoantibodi
ro
ssa
la
ssb
antigen
diagnosi
secondari
ss
base
find
welldefin
connect
tissu
diseas
f
ocular
oral
symptom
presenc
two
object
criteria
among
ocular
sign
salivari
gland
involv
histopatholog
f
patient
clinic
signific
histori
r
cardiopulmonari
gastrointestin
renal
diseas
diabet
mellitu
exclud
addit
patient
clinic
signific
ocular
diseas
elev
intraocular
pressur
mmhg
glaur
coma
uveiti
scleriti
preexist
retinopathi
c
retin
detach
retrobulbar
neuriti
herpet
ulcer
cornea
ocular
cancer
exclud
women
childbear
potenti
requir
use
accept
method
contracept
particip
underw
baselin
medic
ophthalmolog
histori
take
physic
examin
electrocardiographi
ecg
screen
visit
baselin
visit
week
patient
randomli
assign
pilocarpin
placebo
group
use
seal
random
envelop
placebo
made
ident
appear
activ
drug
tablet
suppli
mgi
pharma
inc
investig
particip
blind
treatment
assign
particip
instruct
take
r
one
tablet
studi
medic
water
four
time
daili
qid
mealtim
bedtim
week
record
miss
dose
advers
event
diari
particip
return
studi
site
week
efficaci
safeti
evalu
visit
patient
underw
vital
sign
measur
clinic
laboratori
examin
urinalysi
complet
blood
cell
count
electrolyt
liver
renal
function
test
report
respons
questionnair
medic
prescript
counter
taken
studi
particip
within
day
prior
screen
date
chang
medic
also
record
saliva
secret
w
record
minut
take
studi
medic
physic
examin
medic
ophthalmolog
histori
take
perform
end
studi
studi
approv
institut
review
board
ntuh
written
inform
consent
obtain
studi
particip
treatment
efficaci
assess
base
proport
patient
indic
benefici
respons
questionnair
increas
saliva
product
week
compar
baselin
efficaci
compar
intentiontotreat
analysi
use
last
avail
postdos
observ
vation
ie
end
point
patient
primari
outcom
studi
global
improv
dri
mouth
particip
w
ask
indic
overal
condit
dri
mouth
mm
visual
analog
scale
va
week
visit
compar
felt
begin
studi
respons
va
classifi
follow
mm
indic
nonrespond
wors
mm
indic
nonrespond
chang
mm
indic
respond
improv
assess
symptom
associ
dri
mouth
six
specif
mm
va
question
includ
mouth
dryness
discomfort
mouth
abil
sleep
abil
speak
without
drink
liquid
abil
chew
swallow
food
abil
wear
dentur
also
record
visit
six
question
regard
condit
may
interfer
w
patient
daili
life
respons
rang
mm
dri
extrem
uncomfort
difficult
respect
left
mm
dri
comfort
easi
respect
right
increas
mm
baselin
score
defin
respons
three
question
use
twopoint
categor
respons
ye
format
assess
condit
dri
mouth
within
last
day
prior
visit
week
question
evalu
whether
studi
particip
comfort
mouth
less
dri
mouth
g
felt
easier
speak
without
drink
week
start
studi
medic
extent
use
oral
comfort
agent
evalu
time
basi
three
r
categori
respons
improv
chang
wors
categor
question
patient
f
improv
symptom
answer
ye
classifi
respond
r
chang
worsen
symptom
answer
classifi
nonrespond
saxon
test
modif
use
quantifi
saliva
product
visit
g
subject
first
instruct
take
noth
mouth
least
minut
chew
piec
preweigh
gauz
minut
r
gauz
weigh
chew
minut
chang
weight
gauz
g
repres
patient
saliva
product
period
determin
predos
saliva
product
studi
medic
administ
postdos
saliva
producf
tion
measur
minut
later
effect
studi
medic
saliva
product
quantifi
compar
differ
postdos
predos
saliva
product
f
safeti
evalu
base
result
physic
examin
ecg
conduct
studi
entri
clinic
laboratori
test
conduct
visit
report
advers
experi
vital
sign
measur
dose
hour
take
studi
medic
visit
postdos
period
advers
experi
dose
toler
queri
advers
experi
document
throughout
studi
visit
statist
analysi
perform
statas
r
version
stata
corp
colleg
park
tx
usa
window
twosid
fisher
exact
test
use
compar
categor
data
pilocarpin
placebo
group
wilcoxon
rank
sum
test
use
compar
va
score
saliva
product
two
group
signific
defin
p
valu
less
ss
patient
random
pilocarpin
group
placebo
group
signific
differ
demograph
v
variabl
diseas
characterist
two
group
tabl
frequent
use
medic
hydroxychloroquin
sulfat
mgday
antacid
low
dose
prednisolon
mgday
nonsteroid
antiinflammatori
drug
use
medic
similar
pilocarpin
placebo
group
similar
dropout
rate
initi
patient
placebo
group
pilocarpin
group
complet
studi
p
tabl
placebo
group
one
patient
lost
followup
period
sever
acut
respiratori
syndrom
sar
outbreak
taiwan
two
patient
withdrew
lack
efficaci
contrast
none
patient
pilocarpin
group
discontinu
studi
treatment
due
lack
efficaci
pilocarpin
group
three
patient
withdrew
mark
sweat
four
lost
followup
four
patient
lost
followup
two
withdrew
sar
outbreak
period
reason
discontinu
studi
significantli
differ
pilocarpin
placebo
group
tabl
global
assess
xerostomia
show
signific
proport
patient
pilocarpin
group
improv
sensat
dri
mouth
compar
placebo
group
intentiontotreat
analysi
p
figur
patient
take
pilocarpin
four
time
daili
also
show
signific
improv
xerostomiarel
condit
abil
sleep
abil
speak
without
figur
borderlin
signific
p
abil
chew
swallow
observ
pilocarpin
group
compar
placebo
group
three
patient
placebo
group
four
pilocarpin
group
dentur
wearer
none
patient
either
group
signific
improv
abil
wear
dentur
howev
analysi
va
score
pilocarpin
placebo
group
indic
signific
improv
p
pilocarpin
group
five
six
specif
dri
mouth
symptom
includ
mouth
dryness
mouth
comfort
abil
sleep
abil
speak
abil
swallow
food
p
compar
baselin
addit
improv
va
score
patient
r
pilocarpin
group
also
report
greater
mouth
comfort
less
dryness
found
easier
speak
compar
placebo
group
figur
although
four
patient
pilocarpin
group
vs
placebo
group
experienc
reduc
use
oral
comfort
agent
differ
reach
signific
p
f
saliva
secret
evalu
unit
gminut
increas
saliva
flow
baselin
secret
defin
respons
pilocarpin
group
demonstr
signific
differ
symptomat
relief
oral
symptom
mouth
dryness
mouth
comfort
abil
sleep
abil
speak
without
drink
liquid
abil
chew
swallow
food
borderlin
signific
observ
pilocarpin
group
compar
placebo
group
increas
mm
baselin
score
mm
visual
analog
scale
question
defin
respons
mouth
comfort
f
h
h
l
percentag
syndrom
patient
respons
dri
mouth
symptom
saliva
product
end
point
greater
proport
patient
pilocarpin
group
respond
therapi
compar
placebo
group
experi
comfort
less
dri
mouth
improv
abil
speak
increas
saliva
product
postdos
collect
end
studi
signific
differ
decreas
use
oral
comfort
agent
two
group
observ
end
studi
patient
pilocarpin
group
exhibit
higher
respons
postdos
saliva
product
placebo
group
intentiontotreat
analysi
p
figur
median
increas
saliva
product
pilocarpin
group
also
significantli
greater
placebo
group
gminut
vs
gminut
p
week
signific
respons
global
assess
xerostomia
symptom
associ
dri
mouth
saliva
secret
pilocarpin
group
observ
throughout
studi
period
seriou
advers
event
found
studi
five
patient
pilocarpin
group
experienc
perspir
three
w
withdrew
studi
palpit
report
two
patient
one
pilocarpin
group
placebo
group
particip
toler
studi
medic
signific
alter
blood
pressur
heart
rate
hematopoiet
renal
hepat
profil
note
studi
studi
demonstr
clinic
efficaci
safeti
pilocarpin
mg
four
time
daili
treatment
dri
mouth
patient
ss
taiwan
ethnic
act
predictor
treatment
outcom
diseas
separ
clinic
trial
determin
treatment
respons
patient
dri
mouth
pilocarpin
need
perform
differ
race
studi
patient
ss
taiwan
receiv
pilocarpin
experienc
global
improv
xerostomia
signific
improv
symptom
associ
dri
mouth
includ
mouth
dryness
mouth
comfort
abil
sleep
abil
speak
abil
swallow
food
increas
saliva
secret
baselin
without
seriou
advers
effect
drugdrug
interact
although
sampl
size
small
studi
demonstr
treatment
benefit
pilocarpin
patient
ss
taiwan
studi
larger
sampl
size
need
lack
signific
differ
improv
abil
swallow
wear
dentur
decreas
use
oral
agent
pilocarpin
placebo
group
may
due
rel
small
sampl
size
differ
might
becom
signific
higher
case
number
fix
dose
trial
vivino
et
al
dose
titrat
studi
papa
et
al
pilocarpin
dose
mgday
higher
week
result
signific
global
improv
dri
mouth
well
dri
eye
furthermor
increas
saliva
flow
also
note
dose
interv
minut
evalu
clinic
effect
pilocarpin
dri
eye
purf
pose
evalu
efficaci
safeti
pilocarpin
treatment
xerostomia
patient
ss
taiwan
demonstr
treatment
pilocarpin
dose
mgday
higher
patient
ss
result
improv
symptom
sign
intraor
dryness
also
allevi
sicca
manifest
dri
eye
dri
skin
vagin
dryness
xeros
inde
recent
random
control
studi
also
confirm
benefici
effect
oral
pilocarpin
ocular
symptom
patient
ss
ethnic
appear
affect
treatment
efficaci
pilocarpin
tablet
patient
ss
among
caucasian
orient
black
origin
trial
studi
demonstr
pilocarpin
therapi
benefit
patient
ss
improv
symptom
xerostomia
ss
defici
secretori
respons
salivari
lacrim
gland
lead
dri
mouth
dri
eye
attribut
decreas
f
number
secretori
unit
dysfunct
residu
secretori
unit
despit
dysfunct
residu
glandular
element
exocrin
gland
preserv
neural
innerv
upregul
muscarin
receptor
therefor
excess
muscarin
receptor
exocrin
gland
provid
target
therapeut
use
secretagogu
stimul
secret
exocrin
gland
patient
ss
conceiv
physiolog
role
protect
function
saliva
includ
lubric
digest
phonat
mastic
reminer
mainten
balanc
oral
microflora
buffer
activ
immun
defens
henc
administr
secretagogu
like
pilocarpin
stimul
saliva
product
prefer
use
saliva
substitut
treatment
dri
mouth
ss
patient
pilocarpin
cholinerg
parasympathomimet
agonist
bind
receptor
variou
exocrin
gland
stimul
secretori
function
accord
pharmacokinet
profil
drug
effect
saliva
flow
dosedepend
timerel
peak
effect
hour
durat
hour
therefor
optim
benefit
achiev
four
time
daili
dose
regimen
howev
cholinerg
activ
drug
also
contribut
advers
effect
patient
ss
sweat
urinari
frequenc
flush
fact
sweat
common
drugrel
advers
event
could
major
reason
withdraw
studi
gener
advers
event
tend
decreas
time
might
diminish
start
low
dose
eg
mg
twice
daili
increas
dose
gradual
mainten
dose
mg
four
time
daili
achiev
due
high
efficaci
safeti
stimul
saliva
flow
secretagogu
consid
treatment
choic
symptomat
relief
sicca
syndrom
becom
effect
medic
prevent
dental
oral
complic
patient
ss
conclus
result
studi
suggest
pilocarpin
mg
four
time
daili
week
effect
safe
well
toler
relief
oral
symptom
patient
ss
taiwan
frequent
advers
event
sweat
increas
treatment
withdraw
rate
